CytRx reports upbeat interim study results

CytRx Corp. (Nasdaq: CYTR) reported upbeat interim results from two ongoing Phase 1b studies of aldoxorubicin to treat bone cancer sending the stock price soaring 95 cents to $4.65.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.